|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 389.50 DKK | +3.17% |
|
+2.74% | +19.75% |
| 12:13pm | European Stocks Close Lower in Tuesday Trading; UK Unemployment Rises to 5.1% | MT |
| 12:09pm | Global drugmakers rush to boost US presence as tariff threat looms | RE |
| Capitalization | 1,731B 272B 232B 215B 202B 376B 24,740B 403B 2,478B 979B 11,764B 1,019B 998B 42,930B | P/E ratio 2025 * |
16.9x | P/E ratio 2026 * | 17.5x |
|---|---|---|---|---|---|
| Enterprise value | 1,832B 288B 245B 227B 214B 398B 26,190B 427B 2,623B 1,036B 12,453B 1,079B 1,057B 45,446B | EV / Sales 2025 * |
5.96x | EV / Sales 2026 * | 6.03x |
| Free-Float |
70.25% | Yield 2025 * |
2.99% | Yield 2026 * | 2.92% |
Last Transcript: Novo Nordisk A/S
| 1 day | +3.17% | ||
| 1 week | +2.74% | ||
| Current month | +19.75% | ||
| 1 month | +25.65% | ||
| 3 months | +8.25% | ||
| 6 months | -5.21% | ||
| Current year | +19.75% |
| 1 week | 363 |  | 391.3 |
| 1 month | 302.25 | | 391.3 |
| Current year | 327.1 | | 391.3 |
| 1 year | 266.9 | | 675.2 |
| 3 years | 266.9 | | 1,033.2 |
| 5 years | 210.08 | | 1,033.2 |
| 10 years | 109.1 | | 1,033.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 2025-08-06 | |
| Director of Finance/CFO | 55 | 2018-02-14 | |
Martin Lange
CTO | Chief Tech/Sci/R&D Officer | 56 | 2025-08-06 |
| Director | Title | Age | Since |
|---|---|---|---|
Kasim Kutay
BRD | Director/Board Member | 61 | 2017-03-22 |
| Director/Board Member | 51 | 2018-03-21 | |
Thomas Rantzau
BRD | Director/Board Member | 54 | 2018-03-21 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | +3.79% | 21.31% | 1,470 M€ | |
| +0.30% | 10.45% | 4 M€ | |
| 0.00% | 5.4% | 26 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +3.17% | +2.74% | -29.35% | -18.69% | 262B | |
| +0.49% | -3.22% | +40.43% | +201.24% | 930B | |
| -0.03% | +2.26% | +47.47% | +29.48% | 527B | |
| -0.51% | -3.48% | +23.44% | +42.44% | 379B | |
| -0.23% | +1.02% | +29.64% | +17.51% | 371B | |
| -2.66% | -3.48% | +25.25% | +20.71% | 289B | |
| -1.12% | +0.37% | +28.05% | +35.20% | 278B | |
| +0.61% | +0.86% | +13.46% | -0.68% | 270B | |
| +0.08% | +1.76% | +20.09% | +25.37% | 178B | |
| -0.20% | +2.31% | +34.00% | +50.07% | 155B | |
| Average | -0.06% | +0.57% | +23.25% | +40.26% | 363.9B | |
| Weighted average by Cap. | -0.01% | +0.30% | +28.14% | +68.21% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 307B 48.29B 41.16B 38.14B 35.87B 66.76B 4,395B 71.62B 440B 174B 2,090B 181B 177B 7,627B | 303B 47.62B 40.59B 37.6B 35.37B 65.83B 4,334B 70.61B 434B 171B 2,061B 179B 175B 7,520B |
| Net income | 103B 16.17B 13.78B 12.77B 12.01B 22.36B 1,472B 23.98B 147B 58.24B 700B 60.65B 59.4B 2,554B | 98.29B 15.44B 13.16B 12.19B 11.47B 21.34B 1,405B 22.89B 141B 55.6B 668B 57.89B 56.71B 2,438B |
| Net Debt | 101B 15.93B 13.58B 12.58B 11.83B 22.02B 1,450B 23.62B 145B 57.37B 689B 59.74B 58.51B 2,516B | 96.93B 15.22B 12.98B 12.02B 11.31B 21.05B 1,386B 22.58B 139B 54.83B 659B 57.09B 55.92B 2,404B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-01-20 | 389.50 kr | +3.17% | 7,520,749 |
| 26-01-19 | 377.55 kr | -2.92% | 6,695,226 |
| 26-01-16 | 388.90 kr | +6.49% | 13,935,860 |
| 26-01-15 | 365.20 kr | -3.45% | 7,646,277 |
| 26-01-14 | 378.25 kr | -1.32% | 5,717,794 |
Delayed Quote Nasdaq Copenhagen, January 20, 2026 at 11:20 am
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- NOVO B Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition